Platforms & Assays
Making life better with multiplex molecular diagnostics at the Point of Need
Life is better in so many ways when we can diagnose infectious diseases at the Point of Need. It is immediate, easier and more efficient. Decisions are made quicker, transmission is slowed and ultimately people suffer less.
A supercharged platform, with a fast workflow
A smooth user experience behind each interaction, with an intuitive interface
A ready to use solution, with all its simplicity, accuracy and speed
A ton of tech behind every result, with intelligent multilingual software algorithms.
A huge leap in rapid multiplex PCR testing, with a small, portable, battery-operated system
A rapid multiplex PCR testing system that delivers results in approximately thirty minutes at the Point of Need.
High quality multiplex PCR testing with the simplicity and speed of a lateral flow test
A sustainable respiratory infection control solution with the quality of lab-based PCR testing
Results you can trust, with a simple procedure and reliable testing
Meet the challenges of the ongoing pandemic with a respiratory infection test designed to deliver rapid PCR results on demand, in 35 minutes, at the Point of Need.
As simple as performing lateral flow tests
Results you can trust and rely on
Decisions you can make at first glance
Confidence in all your decisions
A quality Rapid COVID-19 PCR assay that provides results with the simplicity and hands on time of a lateral flow test.
In today’s healthcare environment, every patient expects a quick and accurate diagnosis. QuantuMDx offers an advanced solution that enables healthcare professionals to meet this challenge by addressing their clinical needs.
Our product portfolio has been designed for you to deliver fast, accurate and actionable results in approximately thirty minutes, with a hands-on time of less than one-minute per sample.
Our solution includes a rapid multiplex PCR platform and an expanding test menu.
We plan to expand the menu of tests for Q-POC™, adding a Respiratory panel, Sexually Transmitted Infections (STIs) panel, and HPV, among others, to the current assay portfolio.
If you would like to stay up to date with our developing product portfolio, sign up to our newsletter or get in touch for more information.